Home
Search:
1146 feeds
357 categories
0 articles (<24 hours)
34 registered users

Use the Mobile version
Mobile

Follow our Twitter feed

View our Linkpartners
Links

Username:
Password:

Register | Retrieve

General


RSS FeedsIpsen joins clinical collaboration to evaluate cabozantinib (CABOMETYX®) plus atezolizumab in metastatic non-small cell lung cancer and metastatic castration-resistant prostate cancer
(WorldNews Norway)

 
 

2 july 2020 10:04:50

 
Ipsen joins clinical collaboration to evaluate cabozantinib (CABOMETYX®) plus atezolizumab in metastatic non-small cell lung cancer and metastatic castration-resistant prostate cancer
(WorldNews Norway)
 


Clinical collaboration marks an important milestone in partnership with Exelixis to further develop cabozantinib Participation will provide Ipsen access to the respective study results to support potential future regulatory submissions in its territories PARIS, FRANCE, 02 July 2020 - Ipsen (Euronext: IPN; ADR: IPSEY), today announced it will join the Exelixis and Roche clinical collaboration and participate in the funding of the recently initiated CONTACT-01 and CONTACT-02 global Phase III pivotal trials. CONTACT-01 is evaluating the safety and efficacy of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with metastatic non-small cell lung cancer (NSCLC)...


 
23 viewsCategory: General > Europe > Norway
 
Recipients of disability benefit
(WorldNews Norway)
Ice Group ASA: Final decision on deferment of spectrum payments
(WorldNews Norway)
 
 
blog comments powered by Disqus


Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Nachrichten